Previous 1 2 3 4 5
Luminex Corporation Hosts Planet xMAP Europe Technology Symposium October 3-4, 2006
Luminex(R) Corporation (Nasdaq: LMNX), a leading multiplex bioassay solutions provider, will be conducting the fourth annual Planet xMAP Europe scientific and technology symposium (formerly xSAMPLES) in Amsterdam, The Netherlands, October 3-4, at the Berlage's Exchange. (Thu, 28 Sep 2006 14:31:49 GMT)
Luminex Corporation Hosts Planet xMAP Europe Technology Symposium October 3-4, 2006
Luminex(R) Corporation , a leading multiplex bioassay solutions provider, will be conducting the fourth annual Planet xMAP Europe scientific and technology symposium (formerly xSAMPLES) in Amsterdam, The Netherlands, October 3-4, at the Berlage's Exchange. The Planet xMAP Europe symposium includes presentations and workshops utilizing Luminex's industry leading xMAP(R) technology in clinical (Thu, 28 Sep 2006 14:32:09 GMT)
UB 2020 is helping to make SUNY’s case
The UB 2020 strategic planning process is helping SUNY make a compelling case that public higher education is key to the future of New York State, Chancellor John R. Ryan told members of the UB Council on Monday. (Thu, 28 Sep 2006 15:33:59 GMT)
How Nature Tinkers With The Cellular Clock
The cell cycle is regulated by several layers of control that work very differently. Researchers at the European Molecular Biology Laboratory (EMBL) and the Technical University of Denmark (DTU) have now discovered that they change in a highly coordinated fashion during evolution and evolve remarkably fast. (Thu, 28 Sep 2006 15:50:18 GMT)
Chemical genomic screening identifies novel therapeutic strategies for cancer
A sophisticated new chemical genetic screening strategy that serves as a tool for identifying anticancer compounds may significantly enhance the drug discovery process. Two research papers that describe using this exciting gene expression-based chemical genomic strategy to identify therapeutics for cancer phenotypes previously associated with a poor prognosis and to gain new insight into cancer (Thu, 28 Sep 2006 16:08:32 GMT)
AACR CEO Margaret Foti receives cancer service award
PHILADELPHIA – American Association for Cancer Research Chief Executive Officer Margaret Foti, Ph.D., M.D. (h.c.) will receive the Association of American Cancer Institutes (AACI) Distinguished Service Award for her outstanding contributions to progress in cancer research. (Thu, 28 Sep 2006 16:13:21 GMT)
GE Healthcare Actively Participates in Study to Advance Microarray Technology Towards Clinical Applications
GE Healthcare today announced the publication of the MicroArray Quality Control (MAQC) project, a collaborative effort led by the U.S Food and Drug Administration (FDA) that included 137 participants from 51 academic, government, and commercial institutions over a two year period. (Thu, 28 Sep 2006 16:22:03 GMT)
CEO Margaret Foti Receives Cancer Service Award
American Association for Cancer Research Chief Executive Officer Margaret Foti, Ph.D., M.D. (h.c.) will receive the Association of American Cancer Institutes (AACI) Distinguished Service Award for her outstanding contributions to progress in cancer research. The award will be presented during a special ceremony at the AACI's annual meeting, October 22 - 24, 2006. (Thu, 28 Sep 2006 16:24:54 GMT)
The Pittsburgh Life Sciences Greenhouse Attracts Series A Funding to Region's Life Sciences Community
The Pittsburgh Life Sciences Greenhouse , the private/public partnership focused on putting the region's life sciences industry on a fast track for growth, today announced that its portfolio company, RedPath Integrated Pathology, Inc., a Pittsburgh- based firm involved in the development of advanced molecular technologies for cancer diagnosis, has secured its Series A financing led by NewSpring (Thu, 28 Sep 2006 17:09:00 GMT)
Purdue, IU Tapped For Effort To Find Cancer Biomarkers
(AP) The National Cancer Institute has tapped Purdue University and the Indiana University School of Medicine for a national campaign to find biological markers that can predict which cancer patients will respond best to which treatments. (Thu, 28 Sep 2006 17:27:45 GMT)
IU, Purdue selected for major NCI biomarker tools initiative
INDIANAPOLIS -- The National Institutes of Health's National Cancer Institute has selected a team of scientists from Indiana and Purdue universities to assess and develop the next generation of tools to improve biomarker discovery. (Thu, 28 Sep 2006 17:58:34 GMT)
Life Science Marketing Support Package Unveiled
BioInformatics, LLC unveiled its 2007 Marketing Support Package -- a unique collection of indispensable resources for companies targeting the fast- growing life science market. (Thu, 28 Sep 2006 18:08:00 GMT)
Genetic 'roadmap' charts links between drugs and human disease
Cambridge, MA, Thurs., (Thu, 28 Sep 2006 18:23:52 GMT)
Vanderbilt Cancer Center joins national network
The Vanderbilt-Ingram Cancer Center will receive $7.6 million over the next five years as part of a $35.5 million national initiative from the National Cancer Institute. (Thu, 28 Sep 2006 18:34:48 GMT)
Genetic "Roadmap" Charts Links Between Drugs and Human Disease
A research team led by scientists at the Broad Institute of MIT and Harvard announced today the development of a new kind of genetic "roadmap" that can connect human diseases with potential drugs to treat them, as well as predict how new drugs work in human cells. Called the "Connectivity Map," the new tool and its uses are described in the September 29 issue of Science and in separate (Thu, 28 Sep 2006 19:25:21 GMT)
Plastic biochip speeds up protein detection
A new, fast, and inexpensive way to test for medically important molecules, such the blood clot protein thrombin and faulty proteins present in Alzheimer`s disease, could emerge from research published today in the journal Advanced Materials. (Thu, 28 Sep 2006 19:33:54 GMT)
Celera Identifies FCAR Genetic Polymorphism Associated with Increased Risk for Myocardial Infarction
ROCKVILLE, Md.----Celera Genomics , an Applera Corporation business, today announced a publication describing a genetic polymorphism in the gene encoding the myeloid IgA Fc receptor, the FCAR Asp92Asn polymorphism, associated with increased risk for myocardial infarction and coronary heart disease . (Thu, 28 Sep 2006 20:00:00 GMT)
Medtech Insight and Windhover Information's 2006 Investment in Innovation (In3) East: ''A Preview of Early-Stage
NORWALK, Conn.----Attendees at the Investment in Innovation East: "A Preview of Early-Stage Medical Technology Companies" conference will hear from leaders in the medical technology industry on all aspects of developing and profiting from the hottest new technologies. (Thu, 28 Sep 2006 20:02:00 GMT)
IGIB develops Geno-Cluster through NIMITLI programme
Delhi based Institute of Genomics and Integrative Biology (IGIB) and Jalaja Technologies have jointly developed Geno-Cluster, a bioinformatics software meant for high-end software applications based on concepts, which are fundamental to comparative genomics. (Fri, 29 Sep 2006 02:45:43 GMT)
An infectious agent of deception, exposed through proteomics
PNNL scientists have identified a protein in Salmonella bacteria that enables it to infect immune cells called macrophages. Seen here: Salmonella, isolated from infected macrophrages. (Mildly color-enhanced. Photo credit: Pacific... (Fri, 29 Sep 2006 04:20:34 GMT)
Tech trio leaves the nest
A trio of bioscience companies has hatched from their nests in a Rockville incubator, but they are sticking together. (Fri, 29 Sep 2006 04:23:38 GMT)
Thursday CEO Book Group
This week's contributor is Steve Rosenbaum, who created MTV News Unfiltered and has a new online video tagging site called Magnify Media. Old book: Diamond Age, by Neal Stephenson. While science fiction books aren't usually viewed as relevant to business,... (Fri, 29 Sep 2006 06:17:21 GMT)
Bio-IT Briefs
September 29, 2006 | The National Cancer Institute on Wednesday announced funding for a major component of its $104 million, five-year Clinical Proteomic Technologies Initiative for Cancer (CPTI). Awards totaling $35.5 million over five years will establish a collaborative network of five Clinical Proteomic Technology Assessment for Cancer (CPTAC) teams. (Fri, 29 Sep 2006 06:29:54 GMT)
New Web tool may speed drug discovery
Local scientists have created what they hope will become the Google of drug discovery: a free, Web-based search engine that quickly finds potential new compounds to treat particular diseases. (Fri, 29 Sep 2006 08:29:16 GMT)
Genome on-off switches mapped
To understand a sequenced genome, scientists need to know where and when the genes are switched on - that has come closer for the "lab rat" of the plant world (Fri, 29 Sep 2006 10:41:02 GMT)
US FDA, DCRI form partnership on cardiac safety tools
The US Food and Drug Administration (FDA) today announced a partnership, under the agency's Critical Path Initiative, with Duke Clinical Research Institute (DCRI) to develop a new generation of tools to identify, as early as possible, the potential effects that drugs and devices may have on the heart -- one of the more ominous side effects associated with such products. (Fri, 29 Sep 2006 10:45:34 GMT)
Major Cancer Study Aims To Identify Protein Markers For Early-stage Disease
A team led by Bay Area scientists is one of five nationwide to receive a major grant from the National Cancer Institute to refine and standardize the technologies for identifying biomarkers in the blood -- specific proteins and the patterns they make -- for the early detection of cancer. (Fri, 29 Sep 2006 12:49:07 GMT)
Genetic Variation In Parkinson's Disease Study Yields Results
Researchers at the National Institutes of Health (NIH) have completed one of the first large-scale studies of the role of common genetic variation in Parkinson's disease (PD). While the results fill in some missing pieces of the genetic puzzle, they are primarily of benefit as a starting point for more detailed studies. The information generated by the study is now publicly available in a (Fri, 29 Sep 2006 12:49:27 GMT)
Mercury Compound Found In Fish Damages Pancreatic Cells
Researchers in Taiwan say they have established for the first time that the mercury compound present as a contaminant in some seafood can damage insulin-producing cells in the pancreas. (Fri, 29 Sep 2006 12:50:27 GMT)
UB's growth key to joining realm of great universities
The University at Buffalo needs to grow by 10,000 students, add 750 new faculty and devise a master plan for its campuses if it's going to become a top institution over the next 15 years, its president said Thursday. (Fri, 29 Sep 2006 13:01:15 GMT)
University launches 'Yale Tomorrow' campaign
Yale is launching a development campaign the weekend of Sept. 30 that is expected to seek $3 billion in five years to fund a wide range of University priorities in the 21st century. (Fri, 29 Sep 2006 13:05:23 GMT)
An Infectious Agent of Deception, Exposed Through Proteomics
The most detailed inventory yet of Salmonella proteins teases out how bacteria invade immune cells while evading detection--and presents a promising target for new drugs, vaccines and rapid diagnostics (Fri, 29 Sep 2006 13:25:06 GMT)
Healtheuniverse Presents Adult Stem Cell Technology in Singapore at NGS (National University of Singapore)
Healtheuniverse Inc., a biotechnology development firm specializing in the development and commercialization of biopharmaceutical and biomedical products, announced today that it featured a seminal presentation for the applications of adult stem cell technology. The presentation was in Singapore at NGS Center for Life Sciences. The Company's fat-based stem cell technology is focused on growing (Fri, 29 Sep 2006 13:30:00 GMT)
Cancer Institute selects PU-IU team for research
The Purdue-IU Analytical Proteomics Team has been selected as one of five national centers for cancer research. Selected by the National Cancer Institute, the team was chosen for inclusion in a conglomerate to look at proteomics technology and its usage for the diagnosis and treatment of cancer. (Fri, 29 Sep 2006 14:09:08 GMT)
An Infectious Agent of Deception, Exposed Through Proteomics
Salmonella bacteria, infamous for food poisoning that kills hundreds of thousands worldwide, infect by stealth. They slip unnoticed into and multiply inside macrophages, the very immune system cells the body relies on to seek and destroy invading microbes. (Fri, 29 Sep 2006 14:48:39 GMT)
BIND(TM) Recognized for Innovation in Drug Discovery
SRU Biosystems, Inc. announced today that the Company was recognized at this year's Annual Meeting of the Society for Biomolecular Sciences with one of the conference's "Best Poster" awards. (Fri, 29 Sep 2006 14:59:00 GMT)
Gene Signatures Match Cancer And Other Diseases With Potentially Effective Drugs
In one of the most ambitious spinoffs of the human genome project, researchers at Dana-Farber Cancer Institute, Children's Hospital Boston, the Broad Institute of Harvard and MIT, and other collaborating centers have unveiled a new, systematic approach to drug discovery that matches diseases with potential treatments using a universal language based on cells' distinctive gene activity profiles, (Fri, 29 Sep 2006 15:51:08 GMT)
IPO Watch: Stepping on the Gas
With the Dow closing in on an all-time high, the IPO market is running on all cylinders. (Fri, 29 Sep 2006 17:10:14 GMT)
Rosetta Genomics IPO Expected Next Week
Biotechnology company Rosetta Genomics Ltd. is expected to go public next week, offering 3 million shares at a proposed price between $11 and 13. (Fri, 29 Sep 2006 18:26:32 GMT)
Rosetta Genomics IPO Expected Next Week
Biotechnology company Rosetta Genomics Ltd. is expected to go public next week, offering three million shares and forecasting a price between $11 and $13. (Fri, 29 Sep 2006 18:26:32 GMT)
Rosetta Genomics IPO Expected Next Week
The Israel-based company said it expects proceeds of $32.1 million, or $37.1 million if the underwriters exercise their right to an additional 450,000 shares. The figure assumes a debut price at $12, the midpoint its estimated range. (Fri, 29 Sep 2006 18:28:51 GMT)
Rosetta Genomics IPO Expected Next Week
Biotechnology company Rosetta Genomics Ltd. is expected to go public next week, offering 3 million shares at a proposed price between $11 and 13. (Fri, 29 Sep 2006 18:35:23 GMT)
Rosetta Genomics IPO Expected Next Week
The Israel-based company said it expects proceeds of $32.1 million, or $37.1 million if the underwriters exercise their right to an additional 450,000 shares. The figure assumes a debut price at $12, halfway between its estimated range. (Fri, 29 Sep 2006 18:59:11 GMT)
Team Selected as National Cancer Institute Proteomics Center
Purdue and Indiana universities' proteomics team has been selected as one of five national centers for cancer research. The National Cancer Institute announced its selection of the Purdue-IU Analytical Proteomics Team for inclusion in a new consortium to assess proteomic technology and its applications for diagnosis and treatment of cancer. (Fri, 29 Sep 2006 20:25:07 GMT)
Genetic database to fight disease
Pilot project serves up new uses for old drugs. (Sat, 30 Sep 2006 01:22:06 GMT)
International Team Analyzes Human Genetic Variation In Key Immune Region
An international group of researchers have unveiled a detailed map of human genetic variation within the major histocompatibility complex (MHC), the most important region of the human genome encoding the human response to infection, autoimmune disease and organ transplantation. (Sat, 30 Sep 2006 15:49:07 GMT)
Previous 1 2 3 4 5
